Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences announces new interim data from Phase 1b/2 study of light-activated AU-011 for the treatment of primary choroidal melanoma.